Sarepta (SRPT) Target Cut to $45 at Wedbush, Analyst Expects Larger Eteplirsen Trial
Tweet Send to a Friend
Wedbush maintained an Outperform rating on Sarepta Therapeutic (NASDAQ: SRPT) and lowered its price target to $45.00 (from $60.00). The ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
